This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Caregen Co., Ltd.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Young-Min Lee: Innovating in Immunotherapy with Peptide Research
Introduction: Young-Min Lee is a prominent inventor based in Siheung-si, South Korea, known for his innovative contributions to the field of immunotherapy. With a focus on developing solutions to combat Th1-mediated immune diseases, Lee has made significant strides in medical science through his research and insights. His notable work is encapsulated in a patent that showcases his dedication to enhancing therapeutic options in medicine and cosmetics.
Latest Patents: Young-Min Lee holds a patent for a "Peptide for inducing mast cell-specific apoptosis and use thereof." This groundbreaking peptide functions similarly to natural CTLA-4, featuring excellent skin penetration due to its small size. The peptide effectively binds to antigen presenting cell surface proteins (CD80 and CD86), inhibiting T cell activity and consequently reducing the expression of inflammatory cytokines such as IL-2 and IFN-γ. The implications of this patent are profound, as the composition could provide significant benefits in the prevention, treatment, or improvement of various immune diseases.
Career Highlights: Young-Min Lee is affiliated with Caregen Co., Ltd., a leading company in the field of pharmaceuticals and cosmetics. His work reflects the company's commitment to innovative research aimed at developing new therapeutic solutions. With a solid foundation in peptide research, Lee continues to push the boundaries of what is possible in medical treatments.
Collaborations: Throughout his career, Young-Min Lee has collaborated with esteemed colleagues, including Young Ji Chung and Eun Mi Kim. These partnerships highlight the collaborative nature of research in the scientific community, as they work together to explore and expand the therapeutic potential of peptides in various applications.
Conclusion: Young-Min Lee's contributions to immunotherapy through his innovative peptide research represent a vital advancement in addressing Th1-mediated immune diseases. His patent demonstrates the potential for impactful solutions in medicine, quasi-drugs, and cosmetics, underscoring the importance of innovation in improving health outcomes. As he continues his work at Caregen Co., Ltd., Lee remains a key figure in the pursuit of scientific excellence and therapeutic advancement.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile